Kurzfassung

A phase III randomised, double-blind, controlled, parallel group study of intravenous Volasertib in combination with subcutaneous low-dose Cytarabine vs. placebo + low-dose Cytarabine in patients 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy